PI3K kinase has a prominent role in the B-cell receptor signaling. Copanlisib, a pan-PI3K inhibitor with predominant selectivity to PI3Kα and PI3Kδ, is Food and Drug Administration (FDA) approved for the treatment of patients with relapsed or refractory follicular lymphoma, and it is currently under clinical development in other indolent lymphomas including marginal zone lymphoma (MZL). However some patients might eventually relapse because of acquired resistance and so a better understanding of resistance mechanisms is needed. Thus we generated MZL cell lines resistant to copanlisib which could help to design improved therapies
A. Arribas, S.N. (2020). Secondary resistance to the PI3K inhibitor copanlisib in marginal zone lymphoma. EUROPEAN JOURNAL OF CANCER, 138(2), 40-40 [10.1016/S0959-8049(20)31181-3].
Secondary resistance to the PI3K inhibitor copanlisib in marginal zone lymphoma
M. Barreca;
2020-01-01
Abstract
PI3K kinase has a prominent role in the B-cell receptor signaling. Copanlisib, a pan-PI3K inhibitor with predominant selectivity to PI3Kα and PI3Kδ, is Food and Drug Administration (FDA) approved for the treatment of patients with relapsed or refractory follicular lymphoma, and it is currently under clinical development in other indolent lymphomas including marginal zone lymphoma (MZL). However some patients might eventually relapse because of acquired resistance and so a better understanding of resistance mechanisms is needed. Thus we generated MZL cell lines resistant to copanlisib which could help to design improved therapies
| File | Dimensione | Formato | |
|---|---|---|---|
|
European Journal of Cancer 138S2 (2020) S1–S62_S40.pdf
accesso aperto
Descrizione: Abstract
Tipologia:
Versione Editoriale
Dimensione
51.24 kB
Formato
Adobe PDF
|
51.24 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
